SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending after a $175 million private equity placement caused an initial stock drop, with the community actively debating whether the dilution is an overreaction or a strategic move that provides capital for significant growth initiatives and positions the company for anticipated NASA contracts.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending after a substantial Q4 earnings beat, driven by surging USDC adoption and revenue, which has ignited bullish enthusiasm for its future potential and a potential short squeeze, while some investors remain wary of regulatory hurdles and valuation.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is experiencing extreme volatility following revised guidance that anticipates a significant near-term revenue decline due to issues with acquisition costs and algorithm changes. This has ignited a fierce debate within the community, with many investors seeing a deep value opportunity given the company's cash reserves and buyback plan, while others voice concerns over the business outlook and allegations from a recent short report.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community debates its innovative GaN and SiC power platforms for next-gen AI data centers and grid infrastructure, with optimism for future contracts from hyperscalers like NVIDIA clashing against concerns over recent revenue declines and the current absence of major, confirmed orders.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is surging after delivering strong earnings and an optimistic fiscal outlook, fueling bullish sentiment around its expansion and triggering a short squeeze. The community is sharply divided, with bulls emphasizing growth potential and analyst upgrades, while bears caution against its high valuation and mixed underlying fundamentals compared to competitors like Chipotle.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is the focus of intense market discussion ahead of its impending earnings report, with widespread anticipation that its results will heavily influence the direction of the broader AI and tech sectors. Community sentiment is sharply divided, speculating whether a likely earnings beat will propel the stock to new highs or lead to a "sell the news" event, compounded by high options volatility.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing a sharp sell-off despite beating Q4 earnings estimates, as investors grapple with the company's fiscal 2027 outlook and intensified debate over AI's potential disruption to the broader enterprise software sector.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is soaring after its nomlabofusp program received FDA Breakthrough Therapy Designation for Friedreich's ataxia, fueling significant community excitement around its potential for accelerated approval and driving speculation of high price targets and a possible big pharma buyout.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is a prominent trending topic, fueled by strong community conviction in its innovative cancer therapy, Anktiva, which is driving a belief in an impending short squeeze amid high short interest and anticipation of upcoming regulatory milestones and clinical updates.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is generating buzz with its aggressive deployment of institutional privacy features via EY Nightfall and a new Web2-to-Web3 SDK (Starkzap), alongside rising DeFi metrics and strategic cross-chain expansions to Solana, solidifying its position as a technically advanced, long-term infrastructure play for a quantum-resistant and scalable future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of "Hold" by Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One investment...

X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan

X4 Pharmaceuticals (NASDAQ:XFOR) Executive Chair Adam Craig said the company's near-term focus is centered on advancing mavorixafor in chronic neutropenia, as the company seeks to position itself as...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given a consensus recommendation of "Hold" by the five research firms that are currently covering the firm, MarketBeat.com...

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has been assigned a consensus rating of "Hold" from the five ratings firms that are currently covering the company, Marketbeat reports. One...

Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1%

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling...

Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC

Acorn Capital Advisors LLC lowered its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 97.9% in the second quarter, according to the company in its most recent filing with...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are presently covering the stock, Marketbeat.com reports...

X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research

Zacks Research lowered shares of X4 Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XFOR News

XFORX4 Pharmaceuticals Inc